Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hepatocellular cancer (HCC) has always been considered a therapeutic challenge, given the cytoxic drug resistant nature of the cancer and associated disorder in liver function, reducing the safety of many conventional chemotherapy agents. The Multikinase inhibitor sorafenib has been found to prolong survival in patients with advanced HCC, by around 3months compared to placebo, but novel treatments need to be explored. Current experimental therapeutic approaches encompass a broad range of science, ranging from intrahepatic irradiation to virus directed immunotherapy. This chapter presents a horizon scan of novel treatments which are currently at early stages of trial development.

Original publication

DOI

10.1016/j.canlet.2009.07.001

Type

Journal article

Journal

Cancer Lett

Publication Date

01/12/2009

Volume

286

Pages

114 - 120

Keywords

Antineoplastic Agents, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Placebos, Protein Kinase Inhibitors